Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 1;77(21):e123-e126.
doi: 10.1158/0008-5472.CAN-17-0341.

"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource

Affiliations

"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource

Katherine C Kurnit et al. Cancer Res. .

Abstract

High-throughput genomic and molecular profiling of tumors is emerging as an important clinical approach. Molecular profiling is increasingly being used to guide cancer patient care, especially in advanced and incurable cancers. However, navigating the scientific literature to make evidence-based clinical decisions based on molecular profiling results is overwhelming for many oncology clinicians and researchers. The Personalized Cancer Therapy website (www.personalizedcancertherapy.org) was created to provide an online resource for clinicians and researchers to facilitate navigation of available data. Specifically, this resource can be used to help identify potential therapy options for patients harboring oncogenic genomic alterations. Herein, we describe how content on www.personalizedcancertherapy.org is generated and maintained. We end with case scenarios to illustrate the clinical utility of the website. The goal of this publicly available resource is to provide easily accessible information to a broad oncology audience, as this may help ease the information retrieval burden facing participants in the precision oncology field. Cancer Res; 77(21); e123-6. ©2017 AACR.

PubMed Disclaimer

Figures

Figure 1
Figure 1. PODS Database
Workflow overview for the development of gene pages. Blue boxes indicate sections included on the website for each gene. Orange boxes indicate resources outside of the Precision Oncology Decision Support (PODS) database that are used to help generate gene page content. Solid lines indicate workflow progression; bidirectional arrows indicate processes that flow in both directions; dashed arrows indicate resources and databases used during that step.

References

    1. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33:2753–62. - PMC - PubMed
    1. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, et al. A decision support framework for genomically informed investigational cancer therapy. Journal of the National Cancer Institute. 2015;107 - PMC - PubMed
    1. Johnson A, Zeng J, Bailey AM, Holla V, Litzenburger B, Lara-Guerra H, et al. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug discovery today. 2015;20:1433–8. - PMC - PubMed
    1. The University of Texas MD Anderson Cancer Center. Personalized Cancer Therapy: Knowledge Base for Precision Oncology. www.personalizedcancertherapy.org. Accessed: 14 January 2017.
    1. Fathiamini S, Johnson AM, Zeng J, Araya A, Holla V, Bailey AM, et al. Automated identification of molecular effects of drugs (AIMED) Journal of the American Medical Informatics Association : JAMIA. 2016;23:758–65. - PMC - PubMed

Publication types